Navigation Links
GenSpera Announces Generic Name "Mipsagargin" for Lead Drug Candidate G-202 per Recommendation by World Health Organization
Date:9/3/2014

et. The generic names of pharmacologically-related substances demonstrate their relationship by using a common "stem". Using common stems, medical practitioners, pharmacists, or people dealing with pharmaceutical products are able to recognize that the substance belongs to a group of substances having similar pharmacological activity. The generic name mipsagargin includes a novel pre-stem, "gargin," indicating that it is unlike any named drug currently or previously on the market or in development. The pre-stem "gargin" may become an established stem over time, usually as other later developed drugs are recognized to be related in structure or activity to mipsagargin.

Each International Nonproprietary Name is a unique name that is globally recognized and is public property.

About GenSpera

GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is therefore expected to have potential efficacy in a wide variety of tumor types.

Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.

Company presentations are available at: http://www.genspera.com

Watch the Corporate Video: '/>"/>

SOURCE GenSpera
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids
2. GenSpera to Present at Rodman & Renshaw 16th Annual Global Investment Conference
3. GenSpera Presents G-202 HCC Clinical Trial Update at 5th Asia-Pacific Primary Liver Cancer Expert Meeting
4. Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
5. Cepheid Announces European Release of Xpert TV, a Next-Generation Molecular Test for Rapid and Accurate Identification of Trichomonas vaginalis Infections
6. MarketResearch.com Announces Addition of New Kalorama Information Content to Diagnostics Knowledge Center
7. CVS Caremark Announces Corporate Name Change to CVS Health to Reflect Broader Health Care Commitment
8. Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome
9. Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021
10. Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043
11. Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today it will report fourth ... open on Wednesday, March 25, 2015, followed by ... Eastern. Conference Call & Webcast: ... Domestic: , 800-753-9057International: , 913-981-5571Conference ID: , ...
(Date:3/5/2015)... und TÜBINGEN, Deutschland, 5. März ... Gates Stiftung und das deutsche biopharmazeutische Unternehmen ... 46 Millionen Euro (52 Millionen US-Dollar) in ... Bereich der medizinisch angewandten Messenger-RNA (mRNA). Auf ... Ansätze zur Behandlung von Krankheiten und zum ...
(Date:3/5/2015)...  As the pharmaceutical industry works to address ... professionals are placing a significant emphasis on company ... by LRN, the leader in Ethics & Compliance ... respondents expressed that clarity on company values is ... training programs (57%), trumping understanding of the PhRMA ...
Breaking Medicine Technology:Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3
... 2010 Results from the VeriStrat analysis of a ... with sorafenib in patients with advanced non-small cell lung ... Symposium on Molecular Targets in Cancer Therapeutics being held ... the VU Medical Center, Amsterdam, The Netherlands.  The intention ...
... SAN DIEGO, Nov. 19, 2010 Marshall Edwards, Inc.(Nasdaq: ... the clinical development of novel anti-cancer therapeutics, announced today ... the Listing Qualifications Staff of The NASDAQ Stock Market ... $10 million stockholders, equity requirement for continued listing on ...
Cached Medicine Technology:VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy 2VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy 3Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing 2Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing 3
(Date:3/5/2015)... Supply & Demand Chain Executive Magazine has ... Know” in the supply chain industry, and we are ... team were included on this year’s list! Russ King ... due to their hard work, their commitment to excellence, ... resolving client needs and challenges. , Russ ...
(Date:3/5/2015)... 05, 2015 Dr. Jonathan Glashow a ... ) has been named by Castle Connolly ... area. Dr. Glashow has been selected by Castle Connolly ... the top specialty care doctors in the tri-state metropolitan ... Connolly program, which carefully screens and selects doctors through ...
(Date:3/5/2015)... As a result of the American ... Clearstream, LLC ’s products, services and company philosophies, ... products—led by their mPulse Hand Sanitizer—fits the core ... The AAPA—which represents a profession comprising than 100,000 ... specialties in the U.S.—advocates and educates on behalf ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Today, ... now running on 100% pollution-free electricity through a ... , As an Arcadia Power Clean Energy ... (EPA) Green Power Partnership requirements, joining national brands ... also purchase clean energy. Earth Source Organics joins ...
(Date:3/5/2015)... Park, California (PRWEB) March 05, 2015 ... (JCAP) last week released a special issue ... in the field of PANDAS (Pediatric Autoimmune Neuropsychiatric ... Neuropsychiatric Syndromes), an autoimmune reaction triggered by infections ... lyme, which result in inflammation of the child's ...
Breaking Medicine News(10 mins):Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3
... has been found that elders in hospitals and care homes are ... this, many of them are said to be in hunger// for ... Ivan Lewis. ,Commencing the ‘Dignity for older people’ campaign ... people should be thoroughly understood. When the food is kept far ...
... Pennsylvania School of Medicine have described a new type ... the patient's thoughts, providing two-way signaling for motor control ... at a junction now of developing a new approach ... Smith, MD, Professor of Neurosurgery and Director of the ...
... Scientists have unlocked the secrets of a deadly superbug that attacks ... ,The news is a vital first step in attempts to ... resistant to current antibiotic treatments. ,Already responsible for ... stages of an epidemic that could result in a massive death ...
... study, published in the March 1, 2007 issue of CANCER, ... termination of this highly effective breast cancer drug may negatively ... that over one third of women have ceased tamoxifen treatment. ... quarter of women treated for breast cancer stop tamoxifen within ...
... traits shape up in natural populations,// but one is led ... Two theories have tried to address this challenge – the ... ,The theory of hitchhiking has indicated that genes ... in natural populations when they "hitch a ride" with healthier ...
... whatever the color”, says Dr.Clive Anderson, consultant dermatologist and ... address is part of a move to get Jamaicans ... of the island’s youth resort to bleaching or lightening ... ,Government health officials plan to launch a ...
Cached Medicine News:Health News:New Ideas on Developing Thought-Controlled Artificial Limbs 2Health News:Tamoxifen Discontinuation Rates Surprisingly High 2Health News:The Evolution of Costly Traits 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: